BioLineRx Ltd.

The US Food and Drug Administration beats the European Medicines Agency to approval of novel agents across the board, but the imbalance is even more stark in oncology, the largest therapy area, a Pin

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Asia Deal Watch is supported by deal intelligence from Biomedtracker. Maruho Obtains Rights To GI-301 No

The most unusual aspect of the dozen applications with September 2023 goal dates at the US FDA is how unusual they aren’t. Standard reviews are the rule, even for the lone breakthrough therapy-designa

The US Food and Drug Administration only needs to approve 10 more novel agents by year-end to match its 2022 count of 45, a number that looks more than feasible given the 40 user fee goal dates for no